Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Next Previous
X
Search
Trial Profile

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions; Registrational
  • Acronyms GALE
  • Sponsors Apellis Pharmaceuticals

    • Most Recent Events

    • 09 Jul 2024 According to an Apellis Pharmaceuticals media release, data from this will be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 17 - 20 in Stockholm, Sweden.
    • 10 Jun 2024 Results presented in an Apellis Pharmaceuticals Media Release.
    • 10 Jun 2024 According to an Apellis Pharmaceuticals media release, positive data (n=792) from this study were presented at the Clinical Trials at the Summit (CTS) Meeting on June 8 in Park City, Utah.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top